◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › O › OMER

Omeros Corporation (OMER) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-16

Omeros Corporation (OMER) operates in the BIOTECHNOLOGY industry and is headquartered in Seattle, United States with about 175 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, OMER reported $0M in revenue and ($3M) in net income.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

Interactive charts & full statements → Open the OMER valuation workbench →

OMER Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$38M	$0M	$0M	$0M	$0M	$91M	$74M	$112M	$30M	$65M	$42M	$14M	$1M	$2M	$6M	$5M	$2M	$1M	$1M	$2M	$0M
Gross Profit	—	—	($1M)	($70M)	($1M)	($1M)	($2M)	$109M	$29M	$64M	$40M	$12M	($26M)	($17M)	$6M	$5M	$2M	$1M	$1M	$2M	$0M
Gross Margin %	—	—	—	—	—	-1.5%	-2.2%	97.6%	98.3%	98.3%	96.6%	92.3%	-4858.8%	-1045.4%	99.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($73M)	($123M)	($169M)	($165M)	($163M)	($174M)	($157M)	($63M)	($112M)	($44M)	($54M)	($71M)	($70M)	($51M)	($37M)	($27M)	($30M)	($21M)	($25M)	($24M)	($24M)
Operating Margin %	-189.5%	—	—	—	—	-191.8%	-212.6%	-56.7%	-375.7%	-67.7%	-130.4%	-527.3%	-12988.5%	-3157.2%	-612.5%	-605.9%	-1430.2%	-1437.5%	-2096.2%	-1268.7%	-11976.5%
Net Income	$125M	($3M)	($157M)	($118M)	$47M	($111M)	($138M)	($84M)	($127M)	($53M)	($67M)	($75M)	($74M)	($40M)	($38M)	($29M)	($29M)	($21M)	($24M)	($23M)	($23M)
Net Margin %	324.9%	—	—	—	—	-123.1%	-187.0%	-75.6%	-424.4%	-82.5%	-160.4%	-555.9%	-13668.5%	-2487.2%	-638.4%	-631.0%	-1389.6%	-1460.5%	-2036.5%	-1200.8%	-11388.5%
EBITDA	$136M	($2M)	($157M)	($143M)	($158M)	($170M)	($168M)	($60M)	($122M)	($42M)	($59M)	($71M)	($70M)	($37M)	($36M)	($26M)	($27M)	($18M)	($24M)	($23M)	($22M)
Earnings Per Share (EPS)	$1.66	$-0.05	$-2.70	$-1.88	$0.76	$-1.79	$-2.41	$-1.71	$-2.61	$-1.17	$-1.65	$-2.00	$-2.22	$-1.39	$-1.59	$-1.29	$-1.37	$-2.92	$-2.22	$-1.62	$-1.60
Shares Outstanding (M)	90M	64M	58M	63M	63M	62M	57M	50M	49M	46M	40M	38M	33M	29M	24M	22M	21M	7M	11M	14M	14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OMER Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$29M	$10M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	$28M	$9M	—	—	($10M)	$0M	—	$0M
Gross Margin %	97.2%	91.6%	—	—	—	-73.1%	—	—
Operating Income (EBIT)	$0M	($17M)	($29M)	($26M)	($32M)	($35M)	($36M)	($35M)
Operating Margin %	0.3%	-176.1%	—	—	—	-8487.6%	—	—
Net Income	$13M	$56M	$86M	($31M)	($25M)	($33M)	($31M)	($32M)
Net Margin %	46.4%	566.7%	—	—	—	-8121.4%	—	—
EBITDA	$18M	$57M	$82M	($21M)	($26M)	($34M)	($33M)	($33M)
Earnings Per Share (EPS)	$0.15	$0.62	$1.36	$-0.47	$-0.43	$-0.58	$-0.54	$-0.56
Shares Outstanding (M)	90M	90M	64M	66M	59M	58M	58M	58M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OMER Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($69M)	($116M)	($149M)	$75M	($86M)	($110M)	($100M)	($60M)	($104M)	($36M)	($52M)	($65M)	($58M)	($30M)	($35M)	($26M)	($15M)	($19M)	($20M)	($14M)	($10M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$8M	$0M	$0M	$1M	$0M
Free Cash Flow (FCF)	($69M)	($116M)	($149M)	$74M	($87M)	($110M)	($100M)	($60M)	($104M)	($37M)	($52M)	($65M)	($58M)	($30M)	($35M)	($27M)	($23M)	($19M)	($20M)	($15M)	($10M)
FCF Margin %	-178.9%	—	—	—	—	-121.5%	-136.0%	-54.0%	-349.2%	-56.4%	-124.1%	-484.5%	-10774.0%	-1868.7%	-584.4%	-594.8%	-1089.8%	-1337.0%	-1695.5%	-772.1%	-5169.0%
Dividends Paid	—	—	—	—	—	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$3M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OMER Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$4M	($15M)	($40M)	($18M)	($22M)	($36M)	($29M)	($32M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$4M	($15M)	($40M)	($18M)	($22M)	($36M)	($29M)	($32M)
FCF Margin %	14.4%	-146.6%	—	—	—	-8709.2%	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OMER Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Assets	$287M	$326M	$277M	$378M	$591M	$419M	$181M	$137M	$96M	$116M	$67M	$49M	$11M	$17M	$27M	$27M	$46M	$62M	$22M	$27M
Cash & Cash Equivalents	$2M	$10M	$3M	$7M	$11M	$101M	$11M	$3M	$6M	$3M	$2M	$1M	$0M	$1M	$2M	$4M	$3M	$1M	$13M	$6M
Total Liabilities	$338M	$447M	$460M	$403M	$505M	$395M	$302M	$246M	($4M)	$119M	$105M	$75M	$54M	$35M	$241M	$33M	$25M	$19M	$113M	$97M
Total Debt (Short + Long-Term)	$135M	$232M	$194M	$227M	$320M	$319M	$240M	$162M	$150M	$85M	$80M	$50M	$33M	$20M	$20M	$19M	$10M	$13M	$17M	$1M
Total Shareholders' Equity	($51M)	($121M)	($183M)	($25M)	$86M	$24M	($121M)	($109M)	$650M	($3M)	($37M)	($26M)	($43M)	($18M)	($215M)	($6M)	$20M	$43M	($91M)	($70M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OMER viewer.

Other Companies in BIOTECHNOLOGY

LBRX · LB Pharmaceuticals Inc Common Stock — $1 billion
ORIC · Oric Pharmaceuticals Inc — $1 billion
IMTX · Immatics NV — $1 billion
CGEM · Cullinan Oncology LLC — $1 billion
MGTX · MeiraGTx Holdings PLC — $1 billion
VOR · Vor Biopharma Inc — $1 billion
MAZE · Maze Therapeutics, Inc. Common Stock — $1 billion
REPL · Replimune Group Inc — $1 billion

← OMDA All “O” companies OMEX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.